← Back to Search

Dietary Supplement

XS Muscle Multiplier for Sarcopenia

N/A
Waitlist Available
Led By David D Church, Ph.D.
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a 5-hour period.
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a drink with essential amino acids to check muscle health in older adults at risk of muscle loss. By seeing how muscles react to these amino acids, doctors can spot problems early, potentially preventing further muscle loss and weakness. Essential amino acids have been shown to effectively stimulate muscle growth and improve muscle mass, strength, and function in elderly individuals.

Eligible Conditions
  • Sarcopenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a 5-hour period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and a 5-hour period. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Resting and Maximum Plasma Leucine Concentration

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 10g of nutritional productExperimental Treatment1 Intervention
All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XS Muscle Multiplier
2022
N/A
~30

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
494 Previous Clinical Trials
150,300 Total Patients Enrolled
8 Trials studying Sarcopenia
188 Patients Enrolled for Sarcopenia
David D Church, Ph.D.Principal InvestigatorUniversity of Arkansas
~8 spots leftby Nov 2025